IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)

NCT03753659 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Pembrolizumab
PROCEDURE: Radio Frequency Ablation (RFA)
PROCEDURE: Microwave Ablation (MWA)
RADIATION: Brachytherapy
DRUG: Transarterial Chemoembolisation (TACE)

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest